High-mobility group box 1 mediates epithelial-to-mesenchymal transition in pulmonary fibrosis involving transforming growth factor-β1/Smad2/3 signaling

Journal of Pharmacology and Experimental Therapeutics

Volumn 354, Issue 3, 2015, Pages 302-309

  Li, Liu Cheng ^a   Li, De Lin ^b,c   Xu, Liang ^c   Mo, Xiao Ting ^b   Cui, Wen Hui ^b   Zhao, Ping ^c   Zhou, Wen Cheng ^b   Gao, Jian ^b   Li, Jun ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c ANHUI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; HIGH MOBILITY GROUP B1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; VIMENTIN; ACTIN; CADHERIN; HMGB1 PROTEIN, HUMAN; HYDROXYPROLINE; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM CELL; LUNG FIBROSIS; LUNG INJURY; LUNG PARENCHYMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; ANIMAL; BLOOD; CELL LINE; EPITHELIUM CELL; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ACTINS; ANIMALS; CADHERINS; CELL LINE; CELL LINE, TUMOR; COLLAGEN TYPE I; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; HMGB1 PROTEIN; HUMANS; HYDROXYPROLINE; PHOSPHORYLATION; PULMONARY FIBROSIS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; VIMENTIN;

EID: 84941554281     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.222372     Document Type: Article

References (39)

1. Chen HH, Zhou XL, Shi YL, and Yang J (2013) Roles of p38 MAPK and JNK in TGFb1- induced human alveolar epithelial to mesenchymal transition. Arch Med Res 44:93-98.
2. Chen T, Nie H, Gao X, Yang J, Pu J, Chen Z, Cui X, Wang Y, Wang H, and Jia G (2014) Epithelial-mesenchymal transition involved in pulmonary fibrosis induced by multi-walled carbon nanotubes via TGF-beta/Smad signaling pathway. Toxicol Lett 226:150-162.
3. Ebina M, Taniguchi H, Miyasho T, Yamada S, Shibata N, Ohta H, Hisata S, Ohkouchi S, Tamada T, and Nishimura H, et al. (2011) Gradual increase of high mobility group protein b1 in the lungs after the onset of acute exacerbation of idiopathic pulmonary fibrosis. Pulm Med 2011:916486.
4. Englert JM, Kliment CR, Ramsgaard L, Milutinovic PS, Crum L, Tobolewski JM, and Oury TD (2011) Paradoxical function for the receptor for advanced glycation end products in mouse models of pulmonary fibrosis. Int J Clin Exp Pathol 4:241-254.
5. Griffin KL, Fischer BM, Kummarapurugu AB, Zheng S, Kennedy TP, Rao NV, Foster WM, and Voynow JA (2014) 2-O, 3-O-desulfated heparin inhibits neutrophil elastase-induced HMGB-1 secretion and airway inflammation. Am J Respir Cell Mol Biol 50:684-689.
6. Hagiwara S, Iwasaka H, Hidaka S, Hasegawa A, Koga H, and Noguchi T (2009) Antagonist of the type-1 ANG II receptor prevents against LPS-induced septic shock in rats. Intensive Care Med 35:1471-1478.
7. Hamada N, Maeyama T, Kawaguchi T, Yoshimi M, Fukumoto J, Yamada M, Yamada S, Kuwano K, and Nakanishi Y (2008) The role of high mobility group box1 in pulmonary fibrosis. Am J Respir Cell Mol Biol 39:440-447.
8. Han G, Zhou YF, Zhang MS, Cao Z, Xie CH, Zhou FX, Peng M, and Zhang WJ (2006) Angelica sinensis down-regulates hydroxyproline and Tgfb1 and provides protection in mice with radiation-induced pulmonary fibrosis. Radiat Res 165:546-552.
9. He M, Kubo H, Ishizawa K, Hegab AE, Yamamoto Y, Yamamoto H, and Yamaya M (2007) The role of the receptor for advanced glycation end-products in lung fibrosis. Am J Physiol Lung Cell Mol Physiol 293:L1427-L1436.
10. He Y, Zhou X, Zheng X, and Jiang X (2013) Exogenous high-mobility group box 1 protein prevents postinfarction adverse myocardial remodeling through TGFb/Smad signaling pathway. J Cell Biochem 114:1634-1641.
11. Hu M, Che P, Han X, Cai GQ, Liu G, Antony V, Luckhardt T, Siegal GP, Zhou Y, and Liu RM, et al. (2014) Therapeutic targeting of SRC kinase in myofibroblast differentiation and pulmonary fibrosis. J Pharmacol Exp Ther 351:87-95.
12. Kalayarasan S, Sriram N, Soumyakrishnan S, and Sudhandiran G (2013) Diallylsulfide attenuates excessive collagen production and apoptosis in a rat model of bleomycin induced pulmonary fibrosis through the involvement of protease activated receptor-2. Toxicol Appl Pharmacol 271:184-195.
13. Kalluri R and Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119:1420-1428.
14. Kao YH, Lin YC, Tsai MS, Sun CK, Yuan SS, Chang CY, Jawan B, and Lee PH (2014) Involvement of the nuclear high mobility group B1 peptides released from injured hepatocytes in murine hepatic fibrogenesis. Biochim Biophys Acta 1842: 1720-1732.
15. Khalil N, Parekh TV, O'Connor R, Antman N, Kepron W, Yehaulaeshet T, Xu YD, and Gold LI (2001) Regulation of the effects of TGF-beta 1 by activation of latent TGF-beta 1 and differential expression of TGF-beta receptors (T beta R-I and T beta R-II) in idiopathic pulmonary fibrosis. Thorax 56:907-915.
16. Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN, Sheppard D, and Chapman HA (2006) Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA 103:13180-13185.
17. King TE Jr, Pardo A, and Selman M (2011) Idiopathic pulmonary fibrosis. Lancet 378:1949-1961.
18. Lee W, Ku SK, Kim JA, Lee T, and Bae JS (2013) Inhibitory effects of epi-sesamin on HMGB1-induced vascular barrier disruptive responses in vitro and in vivo. Toxicol Appl Pharmacol 267:201-208.
19. Li L, Li D, Xu L, Zhao P, Deng Z, Mo X, Li P, Qi L, Li J, and Gao J (2015) Total extract of Yupingfeng attenuates bleomycin-induced pulmonary fibrosis in rats. Phytomedicine 22:111-119.
20. Li LC, Gao J, and Li J (2014a) Emerging role of HMGB1 in fibrotic diseases. J Cell Mol Med 18:2331-2339.
21. Li LC, Li J, and Gao J (2014b) Functions of galectin-3 and its role in fibrotic diseases. J Pharmacol Exp Ther 351:336-343.
22. Liu H, Gu Y, Yin J, Zheng G, Wang C, Zhang Z, Deng M, Liu J, Jia X, and He Z (2014) SET-mediated NDRG1 inhibition is involved in acquisition of epithelial-tomesenchymal transition phenotype and cisplatin resistance in human lung cancer cell. Cell Signal 26:2710-2720.
23. Loomis-King H, Flaherty KR, and Moore BB (2013) Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis. Curr Opin Pharmacol 13: 377-385.
24. Lynch J, Nolan S, Slattery C, Feighery R, Ryan MP, and McMorrow T (2010) Highmobility group box protein 1: A novel mediator of inflammatory-induced renal epithelial-mesenchymal transition. Am J Nephrol 32:590-602.
25. Mateen S, Raina K, Agarwal C, Chan D, and Agarwal R (2013) Silibinin synergizes with histone deacetylase and DNA methyltransferase inhibitors in upregulating E-cadherin expression together with inhibition of migration and invasion of human non-small cell lung cancer cells. J Pharmacol Exp Ther 345: 206-214.
26. Mishra S, Tripathi A, Chaudhari BP, Dwivedi PD, Pandey HP, and Das M (2014) Deoxynivalenol induced mouse skin cell proliferation and inflammation via MAPK pathway. Toxicol Appl Pharmacol 279:186-197.
27. Ogiku M, Kono H, Hara M, Tsuchiya M, and Fujii H (2011) Glycyrrhizin prevents liver injury by inhibition of high-mobility group box 1 production by Kupffer cells after ischemia-reperfusion in rats. J Pharmacol Exp Ther 339: 93-98.
28. Podowski M, Calvi C, Metzger S, Misono K, Poonyagariyagorn H, Lopez-Mercado A, Ku T, Lauer T, McGrath-Morrow S, and Berger A, et al. (2012) Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice. J Clin Invest 122:229-240.
29. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, and Lasky JA, et al.; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788-824.
30. Rowe SM, Jackson PL, Liu G, Hardison M, Livraghi A, Solomon GM, McQuaid DB, Noerager BD, Gaggar A, and Clancy JP, et al. (2008) Potential role of high-mobility group box 1 in cystic fibrosis airway disease. Am J Respir Crit Care Med 178: 822-831.
31. Selman M and Pardo A (2003) The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 29 (3 Suppl): S93-S97.
32. Sullivan BP, Kassel KM, Manley S, Baker AK, and Luyendyk JP (2011) Regulation of transforming growth factor-b1-dependent integrin b6 expression by p38 mitogenactivated protein kinase in bile duct epithelial cells. J Pharmacol Exp Ther 337: 471-478.
33. Vittal R, Zhang H, Han MK, Moore BB, Horowitz JC, and Thannickal VJ (2007) Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases. J Pharmacol Exp Ther 321:35-44.
34. Vyas-Read S, Wang W, Kato S, Colvocoresses-Dodds J, Fifadara NH, Gauthier TW, Helms MN, Carlton DP, and Brown LA (2014) Hyperoxia induces alveolar epithelial-to-mesenchymal cell transition. Am J Physiol Lung Cell Mol Physiol 306: L326-L340.
35. Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Crandall ED, du Bois RM, and Borok Z (2005) Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 166:1321-1332.
36. Xu L, Li LC, Zhao P, Qi LW, Li P, Gao J, and Fei GH (2014a) Total polysaccharide of Yupingfeng protects against bleomycin-induced pulmonary fibrosis via inhibiting transforming growth factor-b1-mediated type I collagen abnormal deposition in rats. J Pharm Pharmacol 66:1786-1795.
37. Xu W, Shao X, Tian L, Gu L, Zhang M, Wang Q, Wu B, Wang L, Yao J, Xu X, et al. (2014b) Astragaloside IV ameliorates renal fibrosis via the inhibition of mitogenactivated protein kinases and antiapoptosis in vivo and in vitro. J Pharmacol Exp Ther 350:552-562.
38. Yao HW, Zhu JP, Zhao MH, and Lu Y (2006) Losartan attenuates bleomycin-induced pulmonary fibrosis in rats. Respiration 73:236-242.
39. Zhang L, Ji Y, Kang Z, Lv C, and Jiang W (2015) Protocatechuic aldehyde ameliorates experimental pulmonary fibrosis by modulating HMGB1/RAGE pathway. Toxicol Appl Pharmacol 283:50-56.